Dr. Abou-Alfa on LY2157299 in HCC

Video

Ghassan K. Abou-Alfa, MD, discusses the phase II study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the phase II study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Abou-Alfa says this is an interesting study because TGF-β1 is an important target in HCC. The study evaluated outcomes based on drops in alpha-fetoprotein (AFP), an associated marker with HCC. However, Abou-Alfa says AFP is not a prognostic or predictive marker.

The median survival was just shy of 6 months for the whole population, but the data for the patients who showed the biggest drop in AFP showed an overall survival of nearly 2 years.

Abou-Alfa says TGF-β1 needs to be studied further and evaluated from this perspective.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD